Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
09/2007
09/20/2007CA2643066A1 Pyrazole compounds
09/20/2007CA2643055A1 Tetralines antagonists of the h-3 receptor
09/20/2007CA2643026A1 Novel enantiomerically pure beta-agonists, method for their production and their use as medicaments
09/20/2007CA2640520A1 Extended cycle multiphasic oral contraceptive method
09/20/2007CA2637597A1 Tetrahydronaphthalene derivatives, processes for preparing them and their use as anti-inflammatory agents
09/20/2007CA2629348A1 Glucagon receptor antagonists, preparation and therapeutic uses
09/20/2007CA2626802A1 Process for making pharmaceutical compositions with a transient plasticizer
09/19/2007EP1835027A1 Novel cancer antigen peptide and the use thereof
09/19/2007EP1834976A1 Anion-binding polymers and uses thereof
09/19/2007EP1834960A2 Immunomodulatory protein derived from the yaba monkey tumor virus
09/19/2007EP1834959A2 Tert-butyl-substituted aromatic steroids having cytoprotective activity
09/19/2007EP1834955A1 Porphyrin derivates and their use as photosensitizers in photodynamic therapy
09/19/2007EP1834954A1 Thiazoles as NF-kB Inhibitors (proteasome inhibitors)
09/19/2007EP1834953A1 Tetrahydropyrane derivatives as 5-lipoxygenase inhibitors
09/19/2007EP1834952A1 Compound for promoting the growth of neural cells
09/19/2007EP1834948A1 Tetrahydronaphtalene derivatives, methods for the production thereof, and their use as antiinflammatory drugs
09/19/2007EP1834947A2 3-substituted amino-1H-indole-2-carboxylic acid and 3-substituted amino-benzo[B]thiophene-2carboxylic acid derivatives as interleukin-4 gene expression inhibitors
09/19/2007EP1834670A2 Anthelmintic compositions containing combinations of avermectins or milbemycins with bis-aryl compounds
09/19/2007EP1834669A1 Use of specific hydrazone compounds for the treatment of viral infections
09/19/2007EP1834650A1 Cancer vaccine preparation
09/19/2007EP1834645A1 Autoinducer synthase modulating compounds and uses therefor
09/19/2007EP1834644A2 Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases
09/19/2007EP1834643A2 Novel medicament comprising a highly potent long-lasting beta2-agonist in combination with other active ingredients
09/19/2007EP1834642A2 2-thioxothiazolidin-4-one compounds and compositions as antimicrobial and antimalarial agents targeting enoyl-ACP reductase of type II fatty acid synthesis pathway and other cell growth pathways
09/19/2007EP1834641A1 Use of CRF1 receptor antagonists for preparing a drug for treating metabolic syndrome and/or obesity and/or dyslipoproteinemia
09/19/2007EP1834640A2 Kappa opiatagonists for treating bladder diseases
09/19/2007EP1834639A1 Remedial agent for fat toxicity
09/19/2007EP1834638A1 Osmotic device containing amantadine and an osmotic salt
09/19/2007EP1834637A1 Preventive/therapeutic composition for free radical disease
09/19/2007EP1834636A1 Compositions comprising porous articles and uses in implantable medical devices
09/19/2007EP1834628A1 Cosmetic composition comprising phytosterols, isoflavones and methylricinoleate, use as inhibitor of 5-alpha-reductase and hair growth
09/19/2007EP1834624A1 Medicinal composition and process for producing the same
09/19/2007EP1833986A1 Determinants of sensitivity to chemotherapeutic agents
09/19/2007EP1833968A1 Cancer specific antibody and cell surface proteins
09/19/2007EP1833967A2 Conserved hbv and hcv sequences useful for gene silencing
09/19/2007EP1833882A1 Hyaluronic acid linked with a polymer of an alpha hydroxy acid
09/19/2007EP1833844A1 Signal peptides, nucleic acid molecules and methods of treatment
09/19/2007EP1833840A2 Potent lna oligonucleotides for the inhibition of hif-1a
09/19/2007EP1833839A1 Quaternary alkaloid derivatives of chelidonium majus l
09/19/2007EP1833836A1 Imidazo-fused thiazolo [4,5-b] pyridine based tricyclic compounds and pharmaceutical compositions comprising same
09/19/2007EP1833835A1 Amorphous tacrolimus and preparation thereof
09/19/2007EP1833834A1 New compounds
09/19/2007EP1833833A2 Polymorphs of 1-(2-methylpropyl)-1h-imidazo 4,5-c 1,5 naphthyridin-4-amine ethanesulfonate
09/19/2007EP1833832A1 Napthyridine compounds as rock inhibitors
09/19/2007EP1833831A1 Substituted heterocyclic compounds and methods of use
09/19/2007EP1833830A1 Quinoline derivative, use and production thereof, and drug containing the same
09/19/2007EP1833829A2 Benzamide substituted imidazo- and pyrrolo-pyridines as protein kinase inhibitors
09/19/2007EP1833826A2 Tricyclic delta-opioid modulators
09/19/2007EP1833825A1 Tricyclic delta-opioid modulators
09/19/2007EP1833824A1 3-cycloalkylcarbonyl indoles as cannabinoid receptor ligands
09/19/2007EP1833823A1 2,5- and 2,6-disubstituted benzazole analogues useful as protein kinase inhibitors
09/19/2007EP1833822A2 Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
09/19/2007EP1833821A2 Sulfamides as endothelin receptor antagonists for the treatment of cardiovascular diseases
09/19/2007EP1833820A1 Selective inhibitors of erk protein kinase and uses therof
09/19/2007EP1833819A1 Pyrazole compounds that modulate the activity of cdk, gsk and aurora kinases
09/19/2007EP1833816A1 Substituted piperidines as renin inhibitors
09/19/2007EP1833812A1 N-[(4, 5-diphenyl-3-alkyl-2-thienyl) methyl]amine (amide, sulfonamide, carbamate and urea) derivatives as cannabinoid cb1 receptor antagonists
09/19/2007EP1833811A1 Oxygen containing heterocycles as glycine transporter inhibiting compounds
09/19/2007EP1833809A1 New benzothiazolecarboxamides
09/19/2007EP1833808A1 New benzothiazolesulfonamides
09/19/2007EP1833807A1 Ubiquitin ligase inhibitors
09/19/2007EP1833806A1 Oxadiazole derivatives as dgat inhibitors
09/19/2007EP1833805A1 New 3-phenylpropionic acid derivatives for the treatment of diabetes
09/19/2007EP1833804A1 Aryl sulphonamide modulators
09/19/2007EP1833803A2 Pharmaceutical compounds as activators of caspases and inducers of apoptosis and the use thereof
09/19/2007EP1833802A2 1,2-diphenyl-imidazole derivatives and their use as cb1 receptor ligands
09/19/2007EP1833797A1 Azacyclic compounds as inhbitors of sensory neurone specific channels (sns)
09/19/2007EP1833795A1 Pyridine compounds for the treatment of prostaglandin mediated diseases
09/19/2007EP1833794A1 3-[2-(3-acylamino-2-oxo-2h-pyridin-1-yl)-acetylamino]-4-oxo-pentanoic acid derivatives and their use as caspase inhibitors
09/19/2007EP1833792A1 Substituted piperidine compounds for use as ccr5 modulators
09/19/2007EP1833791A2 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists
09/19/2007EP1833788A1 Process for preparing perindopril erbumine
09/19/2007EP1833787A2 Indole derivatives for use as ppar active compounds
09/19/2007EP1833782A1 Cycloalkylamine derivatives
09/19/2007EP1833780A1 Methods of making pravastatin sodium
09/19/2007EP1833570A1 Treatment for severe melancholic depression with epa
09/19/2007EP1833511A2 Method of treating brain cancer
09/19/2007EP1833503A2 Pulmonary surfactant formulations
09/19/2007EP1833493A1 Use of polyethylene oxide for urogenital infection inhibition
09/19/2007EP1833492A1 A new use for very low molecular weight heparins
09/19/2007EP1833491A1 Topical compositions comprising one or more of 44-thiouridine, isomaltitol and uridine
09/19/2007EP1833490A2 Rnai modulation of rsv and therapeutic uses thereof
09/19/2007EP1833489A2 Glycolipids and analogues thereof as antigens for nk t cells
09/19/2007EP1833488A2 Casein kinase 2 antisense therapy
09/19/2007EP1833487A1 New use of gabab receptor agonists
09/19/2007EP1833486A1 Treatment product for animals and means for preparing same
09/19/2007EP1833485A2 Prevention of thrombotic disorders with active vitamin d compounds or mimics thereof
09/19/2007EP1833484A1 Use of cgrp antagonists in treatment and prevention of hot flushes in prostate cancer patients
09/19/2007EP1833483A1 Use of selected cgrp antagonists for controlling menopausal hot flashes
09/19/2007EP1833482A2 Compounds and therapeutical use thereof
09/19/2007EP1833481A1 Farnesyl protein transferase inhibitors and methods for treating proliferative diseases
09/19/2007EP1833480A2 Cardiotonic compounds with inhibitory activity against beta-adrenergic receptors and phosphodiesterase
09/19/2007EP1833479A2 1-(2-methylpropyl)-1h-imidazo 4,5-c(1,5 )naphthyridin-4-amine ethanesulfonate and 1-(2-methylpropyl)-1h-imidazoý4,5-c 1,5 naphthyridin-4-amine methanesulfonate
09/19/2007EP1833478A1 Use of selected cgrp antagonists in combination with other antimigraine medical substances for the treatment of migraine
09/19/2007EP1833477A1 Pyrazolo-heteroaryl compounds useful to treat tnf-alpha and il-1 mediated diseases
09/19/2007EP1833476A1 Extended release pharmaceutical composition of celecoxib
09/19/2007EP1833475A2 Use of resolvins to treat gastrointestinal diseases
09/19/2007EP1833474A1 Pharmaceutical compositions based on fluorinated sulphamides and sulphinimides
09/19/2007EP1833473A2 5ht2c receptor modulator compositions and methods of use
09/19/2007EP1833472A2 Use of certain biphenyl compounds for protection of neurons and oligodendrocytes in the treatment of multiple sclerosis (ms)
1 ... 3577 3578 3579 3580 3581 3582 3583 3584 3585 3586 3587 3588 3589 3590 3591 3592 3593 3594 3595 3596 3597 ... 7860